

8-Hour Waiver Training

Buprenorphine for the Treatment of Opioid Use Disorder



Register: bit.ly/3s9mXpi

Learning Objectives

1. Screen and identify patients with OUD and define evidence-based treatments.
2. Discuss the pharmacology of opioids as it relates to treatment of opioid use disorder (OUD) patients.
3. Describe the fundamentals of office-based opioid treatment including the treatment of the co-morbid patient.
4. Explain the process of buprenorphine induction as well as stabilization and maintenance.
5. Discuss all FDA approved antagonist and agonist medications to treat OUD.
6. Discuss basic office protocols including medical record documentation and confidentiality.
7. Utilize evidence-based resources to ensure providers have the confidence to prescribe buprenorphine for patients with OUD.
8. Recognize the importance of obtaining a waiver to begin treating patients with OUD.



Tuesday, February 8, 2022

8:00 am - 5:15 pm



Live, virtual CME training



Eric Weintraub, MD

Principal Investigator & Consultant,
Maryland Addiction Consultation
Service (MACS)

Additional presenters: Avinash Ramprashad, MD
and William Hall, MD

Questions?

MACStraining@som.umaryland.edu

Accreditation

In support of improving patient care, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), the American Academy of PAs (AAPA), American Psychological Association (APA) and Association for Social Work Boards (ASWB) to provide continuing education for the healthcare team. *For additional information, visit the registration page.*



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

MACS

Maryland Addiction Consultation Service

Funding for this initiative was made possible (in part) by grant 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.